NCT02424955View on ClinicalTrials.gov

Feasibility 3D Perfusion Ultrasound for Liver Cancer SABR Planning and Response Evaluation

NACompletedINTERVENTIONAL
Enrollment

11

Participants

Timeline

Start Date

November 18, 2014

Primary Completion Date

June 30, 2022

Study Completion Date

June 30, 2022

Conditions
Liver CancerLiver TumorHepatocellular CarcinomaLiver Carcinoma
Interventions
DRUG

perflutren lipid microspheres

DIAGNOSTIC_TEST

3D ultrasound

Trial Locations (1)

94305

Stanford University, School of Medicine, Stanford

All Listed Sponsors
lead

Stanford University

OTHER

NCT02424955 - Feasibility 3D Perfusion Ultrasound for Liver Cancer SABR Planning and Response Evaluation | Biotech Hunter | Biotech Hunter